This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
RPL13 / Large ribosomal subunit protein eL13 · Western blot design guide
Design a Western Blot for RPL13
Real validated RPL13 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-RPL13 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
RPL13 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~24.3 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Appendix (IHC candidate; verify WB) +4 more | |
| Negative control | Lung (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated + Acetylated | |
| Caveat | Modification-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 2 isoform(s) |
Section 1
Real Curated RPL13 Western Blot Protocols
The M06505 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | MCF7 cell lysate (catalog M06505) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | M06505; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected RPL13 Western Blot Band Size?
RPL13 has a predicted mass of 24.3 kDa; two isoforms could affect migration, but no distinct band pattern or empirical band size is established.
| Band near 24.3 kDa | Consistent with the predicted size of RPL13, pending identity controls |
| Single band near 24.3 kDa | Isoforms 1 and 2 need not resolve as separate bands |
| Two bands at different sizes | Could reflect isoforms 1 and 2 if their identities are confirmed |
| Additional band near the main band | May reflect an isoform, but its migration is not established |
💡Expected RPL13 appearanceUniProt predicts RPL13 at 24.3 kDa; no empirical band size or isoform migration is supplied, so confirm any candidate band with antibody and RPL13 identity controls.
| UniProt predicted mass | Sets the 24.3 kDa reference size, not a measured band position |
| Isoform 1 | Its individual mass and migration are not supplied |
| Isoform 2 | Its individual mass and migration are not supplied |
| Alternative splicing into isoforms 1 and 2 | May produce different sizes, but separate bands are not established |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | RPL13 may be poorly recovered from the cytoplasmic sample | Check lysate preparation, loading, and transfer with controls |
| Band higher than expected | An isoform or unrelated antibody target is possible; the cause is unverified | Compare with RPL13 depletion and an independent antibody |
| Band lower than expected | An isoform or unrelated antibody target is possible; the cause is unverified | Compare with RPL13 depletion and an independent antibody |
| Multiple bands | Isoforms 1 and 2 are annotated, but their separation is unknown | Test which bands decrease after RPL13 depletion |
| Weak or no signal | Low recovery or detection of cytoplasmic RPL13 is possible | Check loading, transfer, and antibody performance with a positive lysate |
Experiment evidence
Western blot images showing RPL13 band
M06505 · RPL13
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for RPL13 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for RPL13 in Western blot, you can use appendix tissue lysate, where HPA reports high expression.
Positive control: Appendix (IHC candidate; verify WB)
Negative control: Lung (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: Cytoplasmic RPL13 should be detectable in tissue lysate; HPA reports no detection in lung, making it a candidate negative control.
HPA tissue expression evidence for RPL13
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | glandular cells | High | Protein (IHC) | HPA → |
| Cerebellum | Purkinje cells | High | Protein (IHC) | HPA → |
| Duodenum | glandular cells | High | Protein (IHC) | HPA → |
| Esophagus | squamous epithelial cells | High | Protein (IHC) | HPA → |
| Fallopian tube | glandular cells | High | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Lung | alveolar cells | Not detected | Protein (IHC) | HPA → |
| Adipose tissue | adipocytes | Low | Protein (IHC) | HPA → |
| Heart muscle | cardiomyocytes | Low | Protein (IHC) | HPA → |
| Lymph node | germinal center cells | Low | Protein (IHC) | HPA → |
| Parathyroid gland | glandular cells | Low | Protein (IHC) | HPA → |
Section 3
Advanced RPL13 Western Blot Tips
Deeper troubleshooting and optimisation questions for RPL13, answered from its protein features.
How should RPL13 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could RPL13 isoforms produce different bands?
Isoforms · UniProt lists isoforms 1 and 2. Isoform 2 lacks residues 88–134, so it may migrate differently. An extra band cannot be assigned to isoform 2 from position alone; check whether the antibody recognizes a sequence retained in that isoform.
Which RPL13 modification sites matter when interpreting bands?
PTM · UniProt lists N6-acetyllysine at 16 and alternate 177, plus phosphoserine at 52, 77, and 106. Residue 106 falls within the region missing from isoform 2. These are UniProt coordinates; antibody or paper numbering may differ. The sites do not establish a visible band shift.
Does this guide establish induction of RPL13?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
What transfer method to use for RPL13 Western blot?
Transfer · RPL13 has a predicted mass of 24.3 kDa. Choose and check a transfer setup that retains proteins near that size. The supplied features specify no membrane type, transfer conditions, or validated method.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the M06505 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should RPL13 bands be quantified?
Quantitation · Define which band or bands you will measure before comparing samples. UniProt lists two isoforms, with residues 88–134 missing from isoform 2, so combining distinct bands could obscure isoform differences. The supplied features do not establish which isoform an observed band represents.
Should RPL13 run exactly at its predicted 24.3 kDa?
Interpretation · 24.3 kDa is the predicted mass; no observed band position is supplied. Use it as a starting reference, not an exact migration target. The listed modifications alone do not establish a visible shift or explain a difference from the predicted mass.
Compare them with the 24.3 kDa predicted mass and consider the shorter isoform 2, which lacks residues 88–134. UniProt also lists acetylation and phosphorylation sites, but their presence does not prove a visible shift. No empirical RPL13 band position is supplied, so band identity needs independent validation.
Compare them with the 24.3 kDa predicted mass and consider the shorter isoform 2, which lacks residues 88–134. UniProt also lists acetylation and phosphorylation sites, but their presence does not prove a visible shift. No empirical RPL13 band position is supplied, so band identity needs independent validation.
Boster reagents
RPL13 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-RPL13 Rabbit Monoclonal Antibody
Cat # M06505
M06505 is a rabbit monoclonal anti-RPL13 antibody listed for human and mouse reactivity. Its supplied Western blot image shows RPL13 expression in MCF7 cell lysate. No publication evidence or additional tested specimens are supplied.
Which to pick: M06505 is the only listed option. It has a Western blot image from MCF7 cell lysate; the supplied image does not show a mouse sample.
Source: BosterBio RPL13 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P26373.
- Human Protein Atlas. RPL13 tissue expression.
- PMC11476868 — target-verified WB comparison
- PMC8724304 — target-verified WB comparison